Gene Therapy and Cell Therapy of Cancer by Means of the Interleukin-18 Gene Transfer
Gene Therapy and Cell Therapy of Cancer by Means of the Interleukin-18 Gene Transfer
批准号:
12470245
负责人:
IMANISHI Jiro
金额:
$3.14万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
IL-18 is originally identified as the IFN-g inducing factor. IL-18 augments cytotoxic activities of CTL and NK cells, and synergizes with effectiveness of IL-12 in the IFN-g production. IL-12 plays critical roles in the induction of the cell-mediated immune responses. It augments proliferation and killing activity of cytotoxic T lymphocyte (CTL) as well as natural killer (NK) cells. IL-12 also facilitates T helper type 1 (Th1) response and induces interferon (IFN)-γproduction. Therefore, transduction of IL-12 and IL-18 genes may enhance both specific and nonspecific anti-tumor immune responses.The EBV plasmids give considerably better results than conventional plasmid vectors when transfected into mammalian cells in combination with any nonviral vehicles. These systems are quite useful for gene therapy of cancer gene therapy. We constructed EBV-based plasmid vectors with murine IL-18 gene expression cassettes. The IL-18 gene was transduced in vivo into preestablished tumor in mice thro … More ugh electroporation, or ex vivo into cultured tumor cell lines via cationic polymer (tumor vaccine). Both in vivo and ex vivo systems achieved quite efficient expression of the cytokine gene, and IL-18 showed quite good anti-therapetic effects especially in vivo systems. Cotransfection with IL-12 gene showed further higher therapeutic outcome, showing that the EBV system enable efficient immuno-gene therapy.The present findings also suggest that the IL-18 gene transfer in vivo, especially when IL12 gene is cotransfected, successfully leads to both specific and non-specific anti-tumoral immune responses. The results from ex vivo experiments strongly suggest that the EBV/lipoplex is quite useful in manipulating an effective tumor cell vaccine that strongly produce IL-12 and IL-18 eliciting powerful Th1 immune responses against tumors. These highly efficient gene transfer system may make it possible to engineer autologous tumor vaccine without drug selection.In conclusions, the IL-18 gene transfer may provide powerful strategies against malignancies, especially metastatic tumors. Less
期刊论文(130)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Fujiwara I. et al.: "Bcl-2 expression in pig cells suppresses the apoptosis caused by human perforin/granzymes- or FasL/Fas-mediated cytotoxicity"Transplant. Proc.. 32. 941-2 (2000)
Fujiwara I. 等人:“猪细胞中的 Bcl-2 表达抑制了人穿孔素/颗粒酶或 FasL/Fas 介导的细胞毒性引起的细胞凋亡”移植。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Huang Y. et al.: "Tumor cytotoxicity of peritoneal macrophages induced by OK-432"Anticancer Drugs. 12. 781-5 (2001)
Huang Y.等:“OK-432诱导的腹膜巨噬细胞的肿瘤细胞毒性”抗癌药物。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Sakakura C. et al.: "Ampllfication and over-expression of the AIB1 nudear receptor co-activator gene in primary gastric cancers"Int. J. Cancer. 89(3). 217-223 (2000)
Sakakura C.等:“原发性胃癌中AIB1核受体共激活基因的扩增和过度表达”Int。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Maruyama- Tabata H. et al.: "Effective Suicide Gene Therapy in vivo by EBV-Based Plasmid Vectors Coupled with Polyamidoamine Dendrimer"Gene Ther.. 7. 53-60 (2000)
Maruyama-Tabata H.等人:“通过基于 EBV 的质粒载体与聚酰胺胺树状聚合物偶联进行体内有效的自杀基因治疗”Gene Ther.. 7. 53-60 (2000)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Arai,Y., 他: "Gene Delivery to Human Chondrocytes by an Adeno-Assodated Virus Vectors."J.Rheumatol.. 27(4). 979-982 (2000)
Arai, Y., 等人:“通过腺相关病毒载体将基因传递至人类软骨细胞。”J.Rheumatol.. 979-982 (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 64 条
Sociomedical study on the attitudes to complementary and alternative medicine
-
批准号:16590561
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.66万
-
财政年份:2004
-
负责人:IMANISHI Jiro
-
依托单位:
Immuno-gene Therapy of Cancer by Interleukin-21 (IL-21)
-
批准号:14571151
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.79万
-
财政年份:2002
-
负责人:IMANISHI Jiro
-
依托单位: